MedDRA

MedDRA

  1. lut 28, 2025

What Does the 'MedDRA’ Mean?

MedDRA stands for Medical Dictionary for Regulatory Activities. It is a standardized medical terminology developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

MedDRA is used internationally to classify adverse event information associated with the use of biopharmaceuticals and other medical products. It provides a consistent way to encode and analyze medical data throughout the regulatory process, from pre-marketing to post-marketing activities.

Why Is the 'MedDRA’ Important in Clinical Research?

MedDRA is crucial in clinical research for ensuring consistency and accuracy in reporting adverse events and medical conditions. Its standardized terminology allows researchers and regulatory authorities to efficiently analyze safety data across different studies, pharmaceutical companies, and geographic regions.

The use of MedDRA facilitates clear communication between stakeholders in the drug development process, including sponsors, investigators, and regulatory agencies. It enhances the quality of safety signal detection and evaluation, ultimately contributing to better patient safety and more effective pharmacovigilance practices.

Good Practices and Procedures

  1. Regularly update to the latest MedDRA version to ensure compliance with current regulatory standards and to benefit from expanded terminology.
  2. Implement a rigorous quality control process for MedDRA coding, including double-coding or peer review of coded terms to maintain consistency.
  3. Conduct periodic training sessions for staff on MedDRA hierarchies and coding principles to ensure accurate and uniform application across studies.
  4. Utilize MedDRA browser tools and standardized MedDRA queries (SMQs) to enhance the efficiency and accuracy of safety signal detection.
  5. Establish clear documentation practices for MedDRA term selection rationales, particularly for complex or ambiguous cases, to ensure traceability and consistency.

Related Terms

Read more

How clinical trials can become a strategic asset for biotech startups

Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…

Advancing PET Innovation at SNMMI 2025

Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…

Insights from Turku PET Symposium 2025

Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…